tirzepatide and vision issues Popular GLP-1 medications used to treat type 2 diabetes obesity—semaglutide (Ozempic and Wegovy) and (Mounjaro and Zepbound)—may be linked to a small increase in the risk of a rare eye Weight-loss drugs Mounjaro Wegovy Ozempic

With more treatment options available and accessible to patients, the more hope the medical community has for reversing the climbing overweight and obesity rates in the United States

It is administered subcutaneously (under the skin) once a week

Tirzepatide is a GIP receptor and GLP-1 receptor agonist

In February 2025, Ozempic lawsuit cases totaled 1,443, an increase of 112 from January 2025, when there were 1,331

This is normal and does not necessarily mean the medication has stopped working

We have set aside a limited supply of the lowest strength for patients with existing orders who may wish to step down in dose and stay on it for the longer term, post the 1st of September